Zymeworks Inc. (NYSE:ZYME) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in Zymeworks Inc. (NYSE:ZYME) by 127.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 715,632 shares of the company’s stock after buying an additional 401,068 shares during the quarter. Dimensional Fund Advisors LP owned about 1.01% of Zymeworks worth $6,090,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Pennant Investors LP purchased a new position in shares of Zymeworks in the 4th quarter valued at about $402,000. Wellington Management Group LLP increased its holdings in Zymeworks by 31.0% in the fourth quarter. Wellington Management Group LLP now owns 205,246 shares of the company’s stock valued at $2,133,000 after buying an additional 48,564 shares in the last quarter. AlphaMark Advisors LLC acquired a new stake in shares of Zymeworks during the 1st quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Zymeworks by 66.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 13,444 shares of the company’s stock worth $141,000 after acquiring an additional 5,344 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Zymeworks during the 1st quarter worth approximately $273,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Zymeworks Price Performance

Shares of Zymeworks stock opened at $12.53 on Wednesday. Zymeworks Inc. has a 1 year low of $6.12 and a 1 year high of $13.27. The business has a 50 day moving average price of $11.55 and a 200 day moving average price of $10.01. The company has a market capitalization of $890.26 million, a P/E ratio of -7.00 and a beta of 1.20.

Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $19.24 million during the quarter, compared to analysts’ expectations of $23.16 million. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. During the same period in the previous year, the firm posted ($0.76) earnings per share. As a group, research analysts expect that Zymeworks Inc. will post -0.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ZYME has been the subject of several research analyst reports. HC Wainwright raised their price objective on Zymeworks from $10.00 to $12.00 and gave the company a “neutral” rating in a research note on Wednesday, September 25th. Stifel Nicolaus raised their price target on Zymeworks from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, August 2nd.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.